Singapore, India reach agreement on resumption of passenger flights: CAAS

Singapore's vaccinated travel lane (VTL) with India will start on November 29, with six designated flights daily from Chennai, Delhi, and Mumbai

PTI

November 21, 2021 / 18:54 IST

Singapore (Image: Reuters)

Singapore has reached an agreement with the Union Ministry of Civil Aviation on the resumption of scheduled commercial passenger flights between the two countries, the Civil Aviation Authority of Singapore (CAAS) said on November 21.

Singapore's vaccinated travel lane (VTL) with India will start on November 29, with six designated flights daily from Chennai, Delhi, and Mumbai, it said. Applications for vaccinated travel passes (VTP) for short-term visitors and long-term pass holders from India will start on Monday.

Airlines can also operate non-VTL flights between India and Singapore, although passengers on non-VTL flights will be subject to the prevailing public health requirements, CAAS said. "CAAS understands that travellers are looking forward to the launch of the VTL and would like to assure travellers that there is no need to rush to apply for the VTP," Channel News Asia reported, citing the authority.

Applications for travellers from Finland, India and Sweden will open the same day at 6 pm Singapore time, it said. "Travellers from these countries will not be able to apply for a VTP earlier (than the stated time)," CAAS said.

The authority said that VTP applications will open for those intending to enter Singapore from November 29 to January 21, 2022. However, it "strongly encouraged" those who intend to enter Singapore after December 1 to apply after November 24.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show